placeholder image
M. M. Dunne All authors
About
Publications While At HealthPartners
selected publications
Journal Article
  • Risk of COVID-19 hospitalization and protection associated with mRNA vaccination among US adults with psychiatric disorders
    Influenza and other respiratory viruses. 2024
  • Vaccine effectiveness against pediatric influenza-A-associated urgent care, emergency department, and hospital encounters during the 2022-2023 season: VISION Network
    Clinical Infectious Diseases. 2024
  • Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: an observational study of real-world data across 10 US states from August-December 2021
    Vaccine. 2023
  • Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION Network, September 2022-April 2023
    American Journal of Transplantation. 2023
  • Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA.4 and BA.5 sublineage periods
    JAMA network open. 2023
  • Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021-February 2022, VISION Network: a retrospective cohort study
    Lancet Reg Health Am. 2023
  • Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network
    Journal of Infectious Diseases. 2023
  • Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults - VISION Network, nine states, September-November 2022
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated - VISION Network, 10 states, December 2021-June 2022
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance - VISION Network, 10 states, December 2021-August 2022
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during oeriods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) vaccine dose against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults - VISION Network, 10 states, December 2021-March 2022
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-nine states, January-September 2021
    American Journal of Transplantation. 2022
  • Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - nine states, January-September 2021
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Contact
    full name
  • M. M. Dunne
  • Quick Info
     
    Collaboration